Dr VG Somani of the Comptroller General of Drugs of India (DCGI) has given the Serum Institute of India (SII) permission to resume the clinical trial of the Oxford Covid-19 candidate vaccine in the country, while also revoking your previous order to suspend any new recruitment for phase two and three trials, depending on PTI.
Dr VG Somani, Comptroller General of Drugs of India (DCGI), authorizes Serum Institute of India to resume clinical trial of Oxford COVID-19 vaccine candidate vaccine in the country, while revoking its previous order to suspend any new recruitment for the phase two and three trial.
– Press Trust of India (@PTI_News) September 15, 2020
On September 12, the Serum Institute of India had said that it would resume clinical trials of AstraZeneca’s Covid-19 candidate vaccine after obtaining permission from the Comptroller General of Drugs of India (DCGI).
Follow live updates on coronavirus here
Pharmaceutical giant AstraZeneca had said on Saturday that clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that the trials they were safe.
Following the suspension of AstraZeneca’s Covid-19 vaccine candidate trials, DCGI had directed the Serum Institute of India to suspend until a new recruitment is ordered in the vaccine candidate’s Phase 2 and 3 clinical trials.
.
